Boehringer ends ‘distraction’ by signing Humira biosimilar deal
Boehringer Ingelheim settles litigation with AbbVie over the possible introduction of its Humira biosimilar and agrees a license to market its competitor in 2023.
Archives for May 15, 2019
FDA chief frames biosimilar insulin as answer to 'intolerable' prices
Acting US FDA commissioner thinks incoming changes to the regulation of insulin may counter the ‘whopping’ price increases seen in recent years.